The stock of Insmed Incorporated (NASDAQ:INSM) is a huge mover today! About 219,042 shares traded hands. Insmed Incorporated (NASDAQ:INSM) has risen 13.40% since April 27, 2016 and is uptrending. It has outperformed by 8.18% the S&P500.
The move comes after 5 months negative chart setup for the $837.02M company. It was reported on Nov, 30 by Barchart.com. We have $13.42 PT which if reached, will make NASDAQ:INSM worth $25.11M less.
Analysts await Insmed Incorporated (NASDAQ:INSM) to report earnings on February, 23. They expect $-0.99 earnings per share, down 94.12% or $0.48 from last year’s $-0.51 per share. After $-0.61 actual earnings per share reported by Insmed Incorporated for the previous quarter, Wall Street now forecasts 62.30% negative EPS growth.
Insmed Incorporated (NASDAQ:INSM) Ratings Coverage
Out of 6 analysts covering Insmed (NASDAQ:INSM), 4 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 67% are positive. Insmed has been the topic of 8 analyst reports since August 10, 2015 according to StockzIntelligence Inc. Stifel Nicolaus initiated Insmed Incorporated (NASDAQ:INSM) on Tuesday, March 15 with “Buy” rating. The stock of Insmed Incorporated (NASDAQ:INSM) earned “Neutral” rating by UBS on Monday, November 9. The firm has “Buy” rating given on Tuesday, October 6 by H.C. Wainwright. The stock has “Hold” rating given by Zacks on Thursday, August 20. The stock of Insmed Incorporated (NASDAQ:INSM) earned “Neutral” rating by Citigroup on Wednesday, March 16. On Monday, August 10 the stock rating was downgraded by Zacks to “Hold”. Zacks upgraded it to “Buy” rating and $27 target price in Friday, September 4 report.
According to Zacks Investment Research, “Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company’s inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.”
Insitutional Activity: The institutional sentiment decreased to 1.15 in 2016 Q2. Its down 0.50, from 1.65 in 2016Q1. The ratio dived, as 11 funds sold all Insmed Incorporated shares owned while 23 reduced positions. 17 funds bought stakes while 39 increased positions. They now own 55.48 million shares or 0.92% less from 56.00 million shares in 2016Q1.
Moreover, Cubist Systematic Strategies Llc has 0.02% invested in Insmed Incorporated (NASDAQ:INSM) for 28,238 shares. Tiaa Cref Investment Mgmt Ltd Liability Corporation owns 235,855 shares or 0% of their US portfolio. Acuta Capital Prtnrs Lc accumulated 1.04% or 220,000 shares. Moreover, California State Teachers Retirement has 0% invested in Insmed Incorporated (NASDAQ:INSM) for 129,848 shares. Renaissance Limited Com holds 149,300 shares or 0% of its portfolio. The New York-based Grp has invested 0% in Insmed Incorporated (NASDAQ:INSM). Princeton Alpha Limited Partnership has 0.02% invested in the company for 10,075 shares. Zurcher Kantonalbank (Zurich Cantonalbank) owns 1,452 shares or 0% of their US portfolio. Janus Mgmt Ltd Company holds 0.02% or 2.85 million shares in its portfolio. Dekabank Deutsche Girozentrale has 0% invested in the company for 35,200 shares. Moreover, Palo Alto Ltd Liability Corporation has 3.76% invested in Insmed Incorporated (NASDAQ:INSM) for 5.05 million shares. The California-based Los Angeles Management & Equity Research has invested 0% in Insmed Incorporated (NASDAQ:INSM). Susquehanna Limited Liability Partnership holds 63,305 shares or 0% of its portfolio. Moreover, Thompson Davis & has 0.01% invested in Insmed Incorporated (NASDAQ:INSM) for 500 shares. Gemmer Asset Mngmt Ltd Liability Corporation last reported 3 shares in the company.
Insider Transactions: Since November 7, 2016, the stock had 0 insider purchases, and 2 selling transactions for $1.48 million net activity. Schaeffer Orlov S Nicole also sold $821,931 worth of Insmed Incorporated (NASDAQ:INSM) shares. $660,150 worth of Insmed Incorporated (NASDAQ:INSM) was sold by Drechsler Andrew T.
More recent Insmed Incorporated (NASDAQ:INSM) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on December 21, 2009. Also Quotes.Wsj.com published the news titled: “News Insmed Inc.INSM” on February 14, 2011. Fool.com‘s news article titled: “Why Insmed Incorporated Shares Skyrocketed” with publication date: June 18, 2014 was also an interesting one.
INSM Company Profile
Insmed Incorporated, incorporated on March 21, 2013, is a biopharmaceutical company. The Firm operates in the segment of development and commercialization of inhaled therapies for patients with serious lung diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.